XBiotech Inc.

XBiotech Inc.

XBIT·NASDAQ

$2.39

-0.27%
HealthcareBiotechnology

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$72.98M
EPS-1.4900
P/E Ratio-1.61
Earnings Date05/14/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

XBiotech Inc.

XBiotech Inc. Earnings Call Transcripts

XBIT · NASDAQ

2017

1
Q1
May 7
Q2
N/A
Q3
N/A
Q4
N/A

2015

1
Q4
May 18
Q1
N/A
Q2
N/A
Q3
N/A